Neuromyelitis Optica (NMO) Clinical Trials and Treatments

Neuromyelitis Optica is an autoimmune disease of the central nervous system characterized by selective inflammation of the optic nerves and spinal cord. The primary pathogenic mechanism involves autoimmunity against aquaporin-4 (AQP4), an astrocytic water channel protein. AQP4-IgG autoantibodies bind to AQP4 on astrocyte foot processes, triggering complement-mediated destruction of astrocytes and oligodendrocytes, leading to demyelination and axonal loss.

The most common symptoms of Neuromyelitis Optica include Acute vision loss from optic neuritis affecting one or both eyes, Eye pain during eye movement, Acute weakness and loss of sensation from spinal cord inflammation, Urinary retention or incontinence from myelitis, Respiratory compromise from cervical myelitis, among others. Approximately 0.3 to 1 per 100,000 people; higher prevalence in non-white populations including African, Asian, and Hispanic populations. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Neuromyelitis Optica from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Neuromyelitis Optica Spectrum Disorder is focused on preventing devastating relapses through immune-targeted therapies that address the specific autoimmune attack. Anti-B cell agents like rituximab, complement inhibitors, IL-6 inhibitors, and anti-IL-2 receptor agents are all being tested.

Yes. As of October 14, 2026, 4 FDA-approved medicines have a current label that names Neuromyelitis Optica: Enspryng (satralizumab), first approved in 2020; Soliris (eculizumab); Ultomiris (ravulizumab-cwvz); and Uplizna (inebilizumab-cdon). Corticosteroids and immune globulins count once each. The FDA is due to decide on Enspryng (satralizumab) by January 10, 2027; the FDA calendar page carries the outcome the day it lands.

The exact cause of Neuromyelitis Optica is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. No causative gene; the diagnostic test is the serum AQP4-IgG antibody, not a genetic test. Approximately 0.3 to 1 per 100,000 people; higher prevalence in non-white populations including African, Asian, and Hispanic populations. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Neuromyelitis Optica. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. No causative gene; the diagnostic test is the serum AQP4-IgG antibody, not a genetic test.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Neuromyelitis Optica clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Neuromyelitis Optica clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.